Drugs / VRX496-transduced autologous CD4 T cells
VRX496-transduced autologous CD4 T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00622232 | Dec 2007 → Jan 2009 | HIV infectious disease | VIRxSYS Corporation | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VRX496-transduced autologous CD4 T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00622232 ↗ |
| Modality | Cell therapy | “VRX496-transduced autologous CD4 T cells” NCT00622232 ↗ |